Value202020212022202320242025TTMCash from investing activities-19.95 M18.92 M-5.04 M-16.71 M4.22 M-2.37 M-2.37 MCash from financing activities46.47 M12.08 M8.24 M24.67 M-16.79 M9.33 M9.33 MFree cash flow-26.76 M-11.74 M-25.63 M-2.47 M7.39 M-13.63 M-13.63 M
Protalix BioTherapeutics Inc (DE)
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.